Certainly, using BTKis in PCNSL, which is largely of the MCD subtype (confirmed by MYD88 and/or CD79B molecular testing), is a rational drug choice, given that the MCD subtype is highly sensitive to BTK inhibition, although some studies suggest that BTKi benefit may be agnostic to MCD variants. Here, MYD88 is linked to primary central nervous system lymphoma.